NEW YORK, July 31, 2024 /PRNewswire/ -- The
global autoinjectors market size is estimated to grow by
USD 303.65 billion from 2024-2028,
according to Technavio. The market is estimated to grow at a CAGR
of over 36.72% during the forecast period. Increasing prevalence of
allergies and need for immediate care is driving market growth,
with a trend towards strategic alliances between companies.
However, side-effects of autoinjectors poses a challenge. Key
market players include AbbVie Inc., Amgen Inc., Bayer AG,
Becton Dickinson and Co., Eli Lilly
and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme
Therapeutics Inc., Johnson and Johnson Services Inc., Johnson
Medtech LLC, medmix Ltd., Merck KGaA, Owen Mumford Ltd.,
Pfizer Inc., RAVIMED Sp. Zoo, Recipharm AB, SHL Medical AG, Teva
Pharmaceutical Industries Ltd., Viatris Inc., and Ypsomed Holding
AG.
Get a detailed analysis on regions, market
segments, customer landscape, and companies- View the
snapshot of this report
Autoinjectors Market
Scope
|
Report
Coverage
|
Details
|
Base year
|
2023
|
Historic
period
|
2018 - 2022
|
Forecast
period
|
2024-2028
|
Growth momentum &
CAGR
|
Accelerate at a CAGR of
36.72%
|
Market growth
2024-2028
|
USD 303655.4
million
|
Market
structure
|
Fragmented
|
YoY growth 2022-2023
(%)
|
27.0
|
Regional
analysis
|
North America, Europe,
Asia, and Rest of World (ROW)
|
Performing market
contribution
|
North America at
41%
|
Key
countries
|
US, UK, Germany,
Canada, and China
|
Key companies
profiled
|
AbbVie Inc., Amgen
Inc., Bayer AG, Becton Dickinson and Co., Eli Lilly and Co., F.
Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Halozyme Therapeutics
Inc., Johnson and Johnson Services Inc., Johnson Medtech LLC,
medmix Ltd., Merck KGaA, Owen Mumford Ltd., Pfizer Inc.,
RAVIMED Sp. Zoo, Recipharm AB, SHL Medical AG, Teva Pharmaceutical
Industries Ltd., Viatris Inc., and Ypsomed Holding AG
|
Market Driver
Strategic alliances have significantly increased in the global
autoinjectors market, with several acquisitions and partnerships
aimed at business expansion through new product offerings. For
instance, Novartis AG formed a commercialization and distribution
agreement with Adamis Pharmaceuticals for the epinephrine
autoinjector SYMJEPI in the US market. This partnership enhanced
Novartis AG's commercial presence and maximized the value of
SYMJEPI. In another development, Halozyme Therapeutics, Inc.
Announced the acquisition of Antares Pharma, Inc., while Pfizer
Inc. Entered into a development agreement with Antares Pharma to
create an autoinjector pen for an undisclosed Pfizer drug. These
alliances enable Antares Pharma to offer a fully packaged product
to Pfizer warehouses at a favorable margin, with Pfizer obtaining
US FDA approval and marketing permission for the combination
product in the future. Such strategic partnerships are expected to
expand the portfolio of pipeline-partnered products for both
companies and increase the potential number of products utilizing
Antares Pharma's innovative QuickShot autoinjector technology
platform, thereby boosting the growth of the global autoinjectors
market.
The Autoinjector market is experiencing significant growth due
to the loss of exclusivity for several biologic drugs. This trend
is driven by the increasing prevalence of chronic conditions like
diabetes, rheumatoid arthritis, hormone deficiency, and
anaphylaxis. Needle phobia and anaphylactic shocks have led to a
high demand for needle-free injectors. Epinephrine autoinjectors,
such as EpiPen and autoinjector pens, are popular for emergency
conditions like anaphylaxis caused by food allergens. Medical
technology advancements include audio visual cues, connectivity,
and faster injection speeds. Spring-powered autoinjectors ensure
safety and accuracy for various drug viscosities. Healthcare
professionals and patients in home care settings benefit from these
advancements. Pharmaceutical industries are investing in
epinephrine autoinjectors for therapy in multiple sclerosis,
asthma, hypertension, and other chronic disorders.
Self-administering patients with auto injectors are increasingly
common for emergency conditions like anaphylactic shock. Bluetooth
connectivity enables real-time monitoring and tracking of drug
usage.
Discover 360° analysis of this market. For
complete information, schedule your consultation - Book
Here!
Market Challenges
- The global autoinjectors market may experience slower growth
due to the potential side effects associated with their use. These
side effects include infections, changes in blood pressure, muscle
pain, headaches, diarrhea, and allergic reactions such as dyspnea,
bronchospasm, tongue edema, skin rash, and urticaria. Patients
undergoing chemotherapy-induced anemia treatment may experience
additional side effects like fatigue, edema, nausea, vomiting,
fever, and hypertension. Furthermore, MS patients using
autoinjectors are at risk of severe hepatic injury and anaphylaxis.
These side effects may discourage patients from adopting
autoinjectors and instead opt for alternatives with fewer side
effects.
- The autoinjector market faces several challenges in delivering
effective and safe solutions for various chronic conditions and
emergency situations. These include the need for audio visual cues
for proper usage, reliable connectivity for dosage recording and
Bluetooth integration, ensuring fast injection speed, addressing
drug viscosities, and enhancing safety and accuracy. Spring-powered
autoinjectors continue to dominate the market, with epinephrine
autoinjectors like EpiPen being well-known. Pharmaceutical
industries and healthcare providers seek advanced features, such as
safety locks, automatic drug reconstitution, and subcutaneous or
intramuscular administration for conditions like anaphylaxis,
multiple sclerosis, asthma, hypertension, and other chronic
disorders. Patients require self-administering autoinjector devices
for emergency conditions like anaphylactic shock, which
necessitates continuous innovation in the market.
For more insights on driver and
challenges - Request a sample report!
Segment Overview
This autoinjectors market report extensively covers market
segmentation by
- Application
- 1.1 Anaphylaxis
- 1.2 Multiple sclerosis
- 1.3 Rheumatoid arthritis
- 1.4 Diabetes
- End-user
- 2.1 Hospitals and clinics
- 2.2 Self-administration
- Geography
- 3.1 North America
- 3.2 Europe
- 3.3 Asia
- 3.4 Rest of World (ROW)
1.1 Anaphylaxis- The anaphylaxis segment dominates
the autoinjectors market due to the rising prevalence of
anaphylaxis and food allergies worldwide. For instance, the CDC
reports that approximately 8% of children in the US have food
allergies, making anaphylaxis a significant concern. Epinephrine, a
first-line treatment for anaphylaxis, is in high demand, leading to
the anticipated growth of the epinephrine market. Mylan, a leading
vendor, offers a generic version of the EpiPen, contributing to the
market's expansion. Other companies are also seeking FDA approval
for their epinephrine autoinjectors. The US, Germany, the UK, and Japan are major markets for epinephrine
autoinjectors. Autoinjector vendors, such as Medeca Pharma AB,
provide self-administration options for anaphylaxis treatments like
Emerade. Instructional videos on vendors' websites demonstrate the
autoinjector application process, further driving market
growth.
For more information on market segmentation with geographical
analysis including forecast (2024-2028) and historic data
(2017-2021) - Download a Sample Report
Research Analysis
Autoinjectors are portable devices used for self-administration
of medications, particularly in emergency conditions such as
anaphylactic shocks caused by food allergens or needle phobia.
These devices deliver precise doses of drugs, including
epinephrine, through a needle or needle-free system, making them
essential for people with chronic disorders like diabetes or those
at risk of anaphylaxis. The market for autoinjectors is growing due
to the loss of exclusivity for some biologics, leading
pharmaceutical industries to invest in new technologies like
Bluetooth-enabled autoinjectors for improved therapy management and
patient safety. Autoinjector pens, syringes, and epinephrine
autoinjectors are commonly used, with the EpiPen autoinjector being
a well-known brand. Healthcare professionals play a crucial role in
educating patients on the proper use of these devices, ensuring
optimal outcomes.
Market Research Overview
Autoinjectors are medical devices used for self-administration
of medications, particularly biologics, in the form of injectable
drugs. With the loss of exclusivity for some blockbuster biologics,
the market for autoinjectors is experiencing significant growth.
Autoinjectors are preferred over traditional syringes for patients
suffering from needle phobia or anaphylactic shocks, such as those
caused by epinephrine for allergic reactions. These devices are
used in home care settings for various chronic conditions like
diabetes, rheumatoid arthritis, hormone deficiency, multiple
sclerosis, asthma, hypertension, and chronic disorders.
Autoinjectors come in different forms, including needle-free
injectors, spring-powered autoinjectors, and autoinjector pens.
They offer features like audio visual cues, connectivity, and
safety and accuracy, making drug delivery easier and more efficient
for healthcare professionals and patients alike. Autoinjectors are
used in emergency conditions like anaphylactic shock, and are
available for various medications, including Adrenaline for food
allergens, and Epinephrine autoinjectors for anaphylaxis.
Pharmaceutical industries are investing in advanced autoinjector
technology, offering features like Bluetooth connectivity, dosage
recording, safety locks, and automatic drug reconstitution, making
self-administration of these medications more convenient and
effective.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
- Application
-
- Anaphylaxis
- Multiple Sclerosis
- Rheumatoid Arthritis
- Diabetes
- End-user
-
- Hospitals And Clinics
- Self-administration
- Geography
-
- North America
- Europe
- Asia
- Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory
company. Their research and analysis focuses on emerging market
trends and provides actionable insights to help businesses identify
market opportunities and develop effective strategies to optimize
their market positions.
With over 500 specialized analysts, Technavio's report library
consists of more than 17,000 reports and counting, covering 800
technologies, spanning across 50 countries. Their client base
consists of enterprises of all sizes, including more than 100
Fortune 500 companies. This growing client base relies on
Technavio's comprehensive coverage, extensive research, and
actionable market insights to identify opportunities in existing
and potential markets and assess their competitive positions within
changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
View original content to download
multimedia:https://www.prnewswire.com/news-releases/autoinjectors-market-size-is-set-to-grow-by-usd-303-65-billion-from-2024-2028--increasing-prevalence-of-allergies-and-need-for-immediate-care-boost-the-market-technavio-302209948.html
SOURCE Technavio